News

Sunshine Heart, C-Pulse, COUNTER HF, study, FDA, heart failure

Sunshine Heart Inc. announced it has received unconditional approval from the U.S. Food and Drug Administration (FDA) to conduct an interim analysis of COUNTER HF, the company's U.S. pivotal study...

Stronger Hearts Helpline, heart failure, telecardiology, California

The National Forum for Heart Disease & Stroke Prevention announced the launch of the Stronger Hearts Helpline, a 24/7 free call-center resource for people with heart failure and...

Quadripolar lead, Medtronic, Attain, VivaQuad, CRT-D

There have been several recent advancements in implantable cardioverter defibrillator (ICD) technology to extend battery life, improvements in patient monitoring to avoid needless shocks, the...

Here are my predictions for technologies to watch in the coming year that have the potential to fundamentally change the practice of cardiology:

Yale, CORE, IV fluids, diuretics, heart failure, study

Many patients hospitalized with severe heart failure are receiving potentially harmful treatment with intravenous fluids, a Yale-led study has found.

Heart failure, remote monitoring, CardioMEMS, St. Jude Medical

Swedish Medical Center is the first facility in the Rocky Mountain Region to implant a new miniaturized, wireless monitoring sensor to manage heart failure (HF).

Case Western Reserve’s chemical compound aimed at restoring spinal cord function may have an additional purpose: stopping potentially fatal arrhythmias after heart attack.

Medtronic announced a partnership agreement between its Cardiocom business and LHC Group.

Ostar Healthcare Technology announced the North American launch of their Cellular P201 telehealth blood pressure monitoring system. This advanced chronic disease remote monitoring system...

EP lab, Implantable Cardioverter Defibrillators, Heart Failure

Boston Scientific Corporation announced the launch and first U.S. implant of its line of Extended Longevity (EL) implantable cardioverter defibrillators (ICD), including Dynagen EL and Inogen EL...

Millions of people take angiotensin receptor blockers (ARBs) to help treat heart failure. But it turns out not all ARBs are created equally, according to one Nova Southeastern University (NSU)...

Blood pressure monitoring, hypertension, heart failure, remote monitoring, OSTAR

Ostar Healthcare Technology, a Washington State Based TeleHealth Solutions company, announced the North American launch of Cellular TeleHealth Blood Pressure Monitoring System.

Artificial Heart, Ventricular Assist Device, Heart failure, SynCardia

SynCardia Systems Inc. has received U.S. Food and Drug Administration (FDA) approval to conduct a clinical study of the effectiveness of the SynCardia temporary Total Artificial Heart for...

CardioKinetix, Parachute, Heart failure

There are several new interventional and minimally invasive surgical heart failure (HF) devices in development or in trials that might offer new ways to boost patient volume in the coming years....

acute heart failure, patient readmission, ER, self-care, challenges

A tool designed to assess what interferes with acute heart failure patients' ability to care for themselves after hospital discharge holds promise for improving patient outcomes and reducing...

Thoratec, HeartMate III, VAD, NewYork Presbyterian, trial, ventricular assist

NewYork-Presbyterian Hospital/Columbia University Medical Center is one of a select group of medical centers participating in a clinical trial of a new device for advanced heart failure patients,...

CardioKinetix Inc. announced the completion of enrollment in Parachute China, a multi-center trial to evaluate the minimally invasive Parachute Ventricular Partitioning Device for the treatment of...

Clinical trial/study, heart failure, Sunshine Heart, C-Pulse System

Sunshine Heart Inc. announced the company's German Erlangen site for the OPTIONS-HF study has implanted its first patient with the C-Pulse(R) System for moderate to severe heart failure. 

Bellerophon Therapeutics LLC announced that it has completed enrollment of its PRESERVATION I clinical trial of Bioabsorbable Cardiac Matrix (BCM), an investigational implantable medical device...

CardioKinetix, Parachute, PARACHUTE III, heart failure, clinical trial

CardioKinetix Inc. announced results of a pooled analysis study of the catheter-based Parachute ventricular partitioning device. Twelve-month clinical data from PARACHUTE III, a study of 100...